Literature DB >> 23265900

Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole and related heterocycles.

James R Burgeson1, Amy L Moore, Dima N Gharaibeh, Ryan A Larson, Natasha R Cerruti, Sean M Amberg, Dennis E Hruby, Dongcheng Dai.   

Abstract

A series of potent arenavirus inhibitors sharing a benzimidazole core were previously reported by our group. SAR studies were expanded beyond the previous analysis, which involved the attached phenyl rings and methylamino linker portion, to include modifications focused on the benzimidazole core. These changes included the introduction of various substituents to the bicyclic benzimidazole ring system along with alternate core heterocycles. Many of the analogs containing alternate nitrogen-based bicyclic ring systems were found to retain antiviral potency compared to the benzimidazole series from which we derived our lead compound, ST-193. In fact, 21 h, built on an imidazopyridine core, possessed a near tenfold increase in potency against Lassa virus pseudotypes compared to ST-193. As found with the benzimidazole series, broad-spectrum arenavirus activity was also observed for a number of the analogs discovered during this study.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23265900     DOI: 10.1016/j.bmcl.2012.11.093

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  5 in total

1.  Identification of Clotrimazole Derivatives as Specific Inhibitors of Arenavirus Fusion.

Authors:  Sylvia Rothenberger; Christian Widmann; Stefan Kunz; Giulia Torriani; Evgeniya Trofimenko; Jennifer Mayor; Chiara Fedeli; Hector Moreno; Sébastien Michel; Mathieu Heulot; Nadja Chevalier; Gert Zimmer; Neeta Shrestha; Philippe Plattet; Olivier Engler
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

2.  Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses.

Authors:  C E Hulseberg; L Fénéant; K M Szymańska-de Wijs; N P Kessler; E A Nelson; C J Shoemaker; C S Schmaljohn; S J Polyak; J M White
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

3.  Lead optimization of an acylhydrazone scaffold possessing antiviral activity against Lassa virus.

Authors:  James R Burgeson; Dima N Gharaibeh; Amy L Moore; Ryan A Larson; Sean M Amberg; Tove' C Bolken; Dennis E Hruby; Dongcheng Dai
Journal:  Bioorg Med Chem Lett       Date:  2013-09-05       Impact factor: 2.823

4.  Structure-activity relationship optimization for lassa virus fusion inhibitors targeting the transmembrane domain of GP2.

Authors:  Guangshun Zhang; Junyuan Cao; Yan Cai; Yang Liu; Yanli Li; Peilin Wang; Jiao Guo; Xiaoying Jia; Mengmeng Zhang; Gengfu Xiao; Yu Guo; Wei Wang
Journal:  Protein Cell       Date:  2019-02       Impact factor: 14.870

Review 5.  Intervention strategies for emerging viruses: use of antivirals.

Authors:  Yannick Debing; Dirk Jochmans; Johan Neyts
Journal:  Curr Opin Virol       Date:  2013-04-04       Impact factor: 7.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.